VERTEX PHARMACEUTICALS INCORPORATED
Proposal 1.1
Election of Class I Director: Sangeeta N. Bhatia
Caisse vote:
For
Applicable policy or principle:
PR_05_01
Proposal 1.2
Election of Class I Director: Jeffrey M. Leiden
Caisse vote:
For
Applicable policy or principle:
PR_05_01
Proposal 1.3
Election of Class I Director: Bruce I. Sachs
Caisse vote:
For
Applicable policy or principle:
PR_05_01
Proposal 2.
Amendments to our charter and by-laws to eliminate supermajority provisions.
Caisse vote:
For
Applicable policy or principle:
PR_05_07
Proposal 3.
Amendment and restatement of our 2013 Stock and Option Plan, to among other things, increase the number of shares available under the plan by 8.0 million shares.
Caisse vote:
Against
Applicable policy or principle:
PR_07_02
Proposal 4.
Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2018.
Caisse vote:
For
Applicable policy or principle:
PR_06
Proposal 5.
Advisory vote on named executive officer compensation.
Caisse vote:
Against
Applicable policy or principle:
PR_07_06
Proposal 6.
Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on the risks to us of rising drug prices.
Caisse vote:
Against
Applicable policy or principle:
PR_12
Proposal 7.
Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.
Caisse vote:
For
Applicable policy or principle:
PR_13_03